Multi-Generation Family Molecular Dog Leukocyte Antigen (DLA) Typing to Select a Hematopoietic Cell Transplant Donor for a Dog with Spontaneous T-Cell Lymphoma
World Small Animal Veterinary Association World Congress Proceedings, 2005
Marilena Lupu1; Theresa Westfall2; Edmund Sullivan2; Benjamin Weigler1; Patrice Stroup1; Eustacia Zellmer1; Marie-Terese Little1; Rainer Storb1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Bellingham Veterinary Critical Care, Bellingham, WA, USA

Canine lymphoma is incurable by chemotherapy alone. However, cures are possible with allogeneic hematopoietic cell transplantation if a suitable DLA matched donor can be identified.

Here, a 7-year-old male Golden Retriever with spontaneous T-cell lymphoma was induced into clinical remission by two chemotherapy cycles. Twenty-eight members of the dog's pedigree from 5 generations and located in 3 countries were identified. Their blood samples and that of the lymphoma dog were tested for highly polymorphic microsatellite markers within the DLA class I (FH 2200) and DLA class II (FH 2202) regions. Segregation analysis of the polymorphisms suggested that 5 family members were DLA matched with the lymphoma dog. This was confirmed by DNA sequencing of DLA-DRB1 alleles. A 13-month-old male donor was chosen, one of his littermate's descendents, from the fourth generation pedigree level. The lymphoma dog was conditioned with two 4 Gy fractions of total body irradiation, delivered 3 hours apart at 7 cGy/min from a 4 MEV linear accelerator, followed by canine G-CSF mobilized peripheral blood mononuclear cells from the donor (3.6 x 10< sup >6< /sup > CD34+ cells/kg) and post-grafting immunosuppression with cyclosporine, 5 mg/kg b.i.d. orally, administered from day-1 to day 35 after transplant. Following the post-irradiation nadir, neutrophil counts normalized by day 10, platelet counts by day 22, and the dog didn't require any blood transfusion support. Chimerism analyses for both granulocyte and lymphocyte fractions showed full donor engraftment as early as 2 weeks after transplant. On day 68 after the transplant, the dog developed graft-vs.-host disease skin lesions, which responded to resumption of cyclosporine therapy.

The dog is now surviving with high quality of life more than 148 days after transplant with complete donor engraftment, controlled graft-vs.-host disease, and no evidence of residual tumor.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Marilena Lupu


MAIN : Abstracts, Oral : Hematopoietic Cell Transplant
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27